Related Experiment Video

Updated: May 20, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Oxazolinodoxorubicin - a promising new anthracycline

Malgorzata Lukawska1, Dagmara Klopotowska, Magdalena Milczarek

  • 1Department of Modified Antibiotics, Institute of Biotechnology and Antibiotics, 5 Staroscinska St., 02-516 Warsaw, Poland. lukawskam@iba.waw.pl

Anticancer Research
|July 4, 2012
PubMed

Insights

Oxazolinodoxorubicin, a novel doxorubicin analog, demonstrates superior anticancer potency and overcomes drug resistance in vitro. This new anthracycline also shows reduced toxicity and comparable antitumor effects in vivo compared to doxorubicin.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Doxorubicin is a widely used chemotherapy agent but faces challenges with drug resistance and toxicity.
  • Development of novel anthracycline analogs is crucial for improving cancer treatment efficacy.
  • Modified daunosamine moieties can alter the pharmacological properties of anthracyclines.

Purpose of the Study:

  • To synthesize and characterize oxazolinodoxorubicin, a novel doxorubicin analog.
  • To compare the in vitro and in vivo properties of oxazolinodoxorubicin with doxorubicin.
  • To evaluate the potential of oxazolinodoxorubicin in overcoming multidrug resistance.

Main Methods:

  • Synthesis of oxazolinodoxorubicin with a modified daunosamine moiety.
  • In vitro cytotoxicity assays against various human tumor cell lines.
  • In vitro drug resistance reversal studies using resistant cancer cell lines.
  • Cellular uptake studies using flow cytometry.
  • In vivo antitumor efficacy and toxicity assessments in NOD/SCID mice.

Main Results:

  • Oxazolinodoxorubicin exhibited higher antiproliferative activity than doxorubicin against multiple human tumor cell lines.
  • The novel compound effectively overcame in vitro drug resistance in various resistant cancer cell lines.
  • Cellular uptake of oxazolinodoxorubicin was significantly higher than doxorubicin in tested cell lines.
  • Oxazolinodoxorubicin demonstrated lower general toxicity and comparable antitumor effects to doxorubicin in vivo.
  • Oxazolinodoxorubicin showed an advantageous biological activity profile.

Conclusions:

  • Oxazolinodoxorubicin is a promising new anthracycline analog with enhanced potency and efficacy against resistant cancers.
  • The modified daunosamine moiety contributes to improved cellular uptake and reduced toxicity.
  • Oxazolinodoxorubicin represents a potential therapeutic advancement in anthracycline-based cancer chemotherapy.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Aryldiazonium Salts to Azo Dyes: Diazo Coupling01:11

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the para position.
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...